Skip to main content

Advertisement

Table 5 Cytotoxicity of compounds 9, 10, 11a, 11b, 12, 13, 14 and 15 against breast carcinoma cell line MCF-7

From: Design, synthesis and evaluation of anticancer activity of novel 2-thioxoimidazolidin-4-one derivatives bearing pyrazole, triazole and benzoxazole moieties

Concentration µg/mL Viability (%)/compound
9 10 11a 11b 12 13 14
500 8.09 6.48 31.79 8.51 6.37 5.96 5.08
250 17.24 15.72 49.81 20.38 14.75 11.74 10.24
125 26.85 24.16 78.26 32.75 23.81 20.82 18.76
62.5 37.51 35.29 89.47 45.06 34.93 27.41 24.95
31.25 45.97 42.81 95.24 61.78 40.84 34.92 30.88
15.6 57.20 51.56 99.71 79.39 49.60 44.73 36.78
7.8 74.19 69.37 100 92.64 70.38 65.46 42.97
3.9 88.43 86.02 100 98.25 81.49 79.25 51.36
2 95.72 93.88 100 100 92.63 90.48 59.28
1 99.34 97.40 100 100 96.75 96.23 72.83
0 100 100 100 100 100 100 100